Jung Cassie
Insider CIK 1960154 · AQST SVP, Operations
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| AQST Aquestive Therapeutics, In | X Exercise deriv | 2026-09-03 | 2026-09-08 | 4,587 | — | $0 | 0 | SEC↗ |
| AQST Aquestive Therapeutics, In | X Exercise | 2026-09-03 | 2026-09-08 | 4,587 | $0.96 | $4.4K | 206,833 | SEC↗ |
| AQST Aquestive Therapeutics, In | X Exercise deriv | 2026-09-03 | 2026-09-08 | 4,587 | — | $0 | 0 | SEC↗ |
| AQST Aquestive Therapeutics, In | X Exercise | 2026-09-03 | 2026-09-08 | 4,587 | $0.96 | $4.4K | 206,833 | SEC↗ |
| AQST Aquestive Therapeutics, In | F Tax w/h | 2026-05-05 | 2026-05-07 | 72,734 | $4.18 | $304.0K | 202,246 | SEC↗ |
| AQST Aquestive Therapeutics, In | S Sale | 2026-03-10 | 2026-03-11 | 45,791 | $4.17 | $190.9K | 274,980 | SEC↗ |
| AQST Aquestive Therapeutics, In | A Award deriv | 2026-03-09 | 2026-03-11 | 42,500 | — | $0 | 42,500 | SEC↗ |
| AQST Aquestive Therapeutics, In | A Award | 2026-03-09 | 2026-03-11 | 80,000 | — | $0 | 320,771 | SEC↗ |
| AQST Aquestive Therapeutics, In | M Exercise deriv | 2025-10-15 | 2025-10-17 | 25,000 | — | $0 | 0 | SEC↗ |
| AQST Aquestive Therapeutics, In | M Exercise | 2025-10-15 | 2025-10-17 | 25,000 | $3.10 | $77.5K | 308,346 | SEC↗ |
| AQST Aquestive Therapeutics, In | S Sale | 2025-10-15 | 2025-10-17 | 67,575 | $7.01 | $473.7K | 240,771 | SEC↗ |
| AQST Aquestive Therapeutics, In | M Exercise deriv | 2025-09-04 | 2025-09-08 | 25,000 | — | $0 | 0 | SEC↗ |
| AQST Aquestive Therapeutics, In | M Exercise deriv | 2025-09-04 | 2025-09-08 | 25,000 | — | $0 | 0 | SEC↗ |
| AQST Aquestive Therapeutics, In | M Exercise | 2025-09-04 | 2025-09-08 | 25,000 | $0.71 | $17.8K | 345,526 | SEC↗ |
| AQST Aquestive Therapeutics, In | S Sale | 2025-09-04 | 2025-09-08 | 62,180 | $5.00 | $310.9K | 283,346 | SEC↗ |
| AQST Aquestive Therapeutics, In | M Exercise | 2025-09-04 | 2025-09-08 | 25,000 | $3.15 | $78.8K | 320,526 | SEC↗ |
| AQST Aquestive Therapeutics, In | F Tax w/h | 2025-03-10 | 2025-03-11 | 2,182 | $2.54 | $5.5K | 295,526 | SEC↗ |
| AQST Aquestive Therapeutics, In | F Tax w/h | 2025-03-09 | 2025-03-11 | 7,997 | $2.65 | $21.2K | 297,708 | SEC↗ |
| AQST Aquestive Therapeutics, In | A Award deriv | 2025-03-07 | 2026-04-13 | 60,000 | — | $0 | 60,000 | SEC↗ |
| AQST Aquestive Therapeutics, In | A Award deriv | 2025-03-07 | 2025-03-11 | 40,000 | — | $0 | 40,000 | SEC↗ |
| AQST Aquestive Therapeutics, In | F Tax w/h | 2025-03-07 | 2025-03-11 | 7,361 | $2.65 | $19.5K | 305,705 | SEC↗ |
| AQST Aquestive Therapeutics, In | A Award | 2025-03-07 | 2025-03-11 | 80,000 | — | $0 | 313,066 | SEC↗ |
| AQST Aquestive Therapeutics, In | S Sale | 2024-11-26 | 2024-11-27 | 44 | $4.87 | $214 | 0 | SEC↗ |
| AQST Aquestive Therapeutics, In | F Tax w/h | 2024-03-10 | 2024-03-12 | 1,132 | $4.88 | $5.5K | 237,754 | SEC↗ |
| AQST Aquestive Therapeutics, In | F Tax w/h | 2024-03-09 | 2024-10-02 | 14,120 | $4.88 | $68.9K | 233,066 | SEC↗ |
| AQST Aquestive Therapeutics, In | F Tax w/h | 2024-03-09 | 2024-03-12 | 8,300 | $4.88 | $40.5K | 238,886 | SEC↗ |
| AQST Aquestive Therapeutics, In | A Award deriv | 2024-03-07 | 2024-03-11 | 50,625 | — | $0 | 50,625 | SEC↗ |
| AQST Aquestive Therapeutics, In | A Award | 2024-03-07 | 2024-03-11 | 101,250 | — | $0 | 247,186 | SEC↗ |
| AQST Aquestive Therapeutics, In | A Award deriv | 2023-08-09 | 2023-08-09 | 55,000 | — | $0 | 55,000 | SEC↗ |
| AQST Aquestive Therapeutics, In | A Award deriv | 2023-05-05 | 2023-05-05 | 55,000 | — | $0 | 55,000 | SEC↗ |
| AQST Aquestive Therapeutics, In | F Tax w/h | 2023-03-10 | 2024-03-11 | 1,365 | — | $0 | 145,936 | SEC↗ |
| AQST Aquestive Therapeutics, In | A Award | 2023-03-09 | 2023-03-09 | 110,000 | — | $0 | 146,747 | SEC↗ |